65,437 trials
Adult Hepatocellular Carcinoma · Advanced Adult Hepatocellular Carcinoma · Endometrial Serous Adenocarcinoma
Primary: Progression Free Survival Rate — 0.52; 0.40; 0.71; 0.84 proportion of patients
Healthy Normals
Primary: Accuracy of Heart Rate Measured in Beats Per Minute Compared to Reference Device — 2.0 beats per minute
Hyperbilirubinemic Encephalopathy
Primary: Bilirubin Induced Neurologic Dysfunction II Score (BIND II) — 1 units on a scale
Musculoskeletal Pain
Primary: Subject's Assessment of Pain Using the Numeric Pain Rating Scale (AUC16h-96h) — 289.18; 341.78; 401.75; 290.55 units on a Scale*hours
Asthma
Primary: Number of Participants Who Experienced One or More Adverse Events — 9; 3 Participants
PRU(Platelet Reactivity Unit) · APT(Antiplatelet Therapy) · HOTPR(High on Treat Platelet Reactivity)
Primary: Numbers of Participants With MACE(Major Adverse Cardiac Event) of Study Subjects — 1; 1; 2 numbers of participants with MACE — p=0.002
Infections, Cytomegalovirus
Primary: Number of CMV Seropositive Subjects With Appearance or Increase of Anti-CMV Tegument Protein IgG Antibodies in Serum. — 5; 2 Participants
Chest Pain
Primary: MACE (Major Adverse Cardiac Events) — 405; 345 Participants
Type 2 Diabetes Mellitus
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Type 2 Diabetes Mellitus
Primary: Percentage of Participants Who Met at Least One New Cerebral and Cardiovascular Events — 1.01 Percentage of Participants
Suicidal Ideation · Suicide, Attempted
Primary: Dot Probe Task — 1.56; -1.65; -1.48; 1.23 milliseconds — p=.034
Premature Ejaculation
Primary: Mean Fold Change in Geometric Mean Intravaginal Ejaculatory Latency Time (IELT) — 2.1; 1.1 No units for fold change
Hypothermia
Primary: Incidence of Hypothermia — 74 Participants
Arthroplasty, Replacement, Hip
Primary: Survival Rate of the Rejuvenate Modular Stem/Neck — 8 Surviving Hips
Depression · Anxiety Disorder
Primary: Percent of Participants Who Develop Major Depression and Anxiety Disorders — 4; 13 Participants — p=0.04